FATE THERAPEUTICS INC (FATE)
US31189P1021 - Common Stock
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Immune Reconstitution Data,...
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage...
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Fate Therapeutics to Present at Upcoming March Investor Conferences
Fate Therapeutics to Present at Upcoming March Investor Conferences
SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage...
Commit To Purchase Fate Therapeutics At $5, Earn 15% Annualized Using Options
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
CIRM Grant Awarded to Support Phase 1 Autoimmunity Study of FT819 CD19-targeted CAR T-cell Program for Systemic Lupus Erythematosus; Study Start-up Ongoing...
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
SAN DIEGO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage...
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock
Billionaire Steve Cohen is taking a massive stake in this little-known biotech company, leading FATE stock to surge more than 17%.
Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a...
Commit To Purchase Fate Therapeutics At $2.50, Earn 30.2% Annualized Using Options
Fate Therapeutics files $300M mixed securities shelf (NASDAQ:FATE)
Fate Therapeutics files preliminary prospectus for mixed shelf offering, aiming to raise $300M; not an offer to sell securities.
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates
Phase 1 Study Open for Enrollment of FT522 ADR-armed, CD19-targeted CAR NK Cell Program for B-cell Lymphoma; Dose Escalation Designed to Assess 3-dose...
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results
SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage...